from the Ariad website...
ARIAD is pursuing a series of related patent applications
on NF-kB, to which it holds an exclusive license.
corporate-ir.net
From Nature Medicine...a new abstact regarding NF-kB
(abstract is accessible from the website without
subscription, so I will re-post it here)
April 1999 Volume 5 Number 4 pp 412 - 417
Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-B
Cun-Yu Wang1, 2, 3, James C. Cusack1, 4, Rong Liu1 & Albert S. Baldwin1, 3, 5
Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-oncogenic therapies such as chemotherapy and radiation effect their responses. Resistance to apoptosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these cancer therapies. The transcription factor NF-B is activated by chemotherapy and by irradiation in some cancer cell lines. Furthermore, inhibition of NF-B in vitro leads to enhanced apoptosis in response to a variety of different stimuli. We show here that inhibition of NF-B through the adenoviral delivery of a modified form of IB, the inhibitor of NF-B, sensitizes chemoresistant tumors to the apoptotic potential of TNF and of the chemotherapeutic compound CPT-11, resulting in tumor regression. These results demonstrate that the activation of NF-B in response to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish the inhibition of NF-B as a new approach to adjuvant therapy in cancer treatment.
1. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7295, North Carolina 27599-7295, USA
2. Department of Endodontics, School of Dentistry,University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA
3. Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA
4. Department of Surgery, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA
5. Department of Biology, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Campus Box 7295, North Carolina 27599-7295, USA
C.-Y.W. & J.C.C. contributed equally to the study
Correspondence should be addressed to A S Baldwin.
also
news-observer.com
Thanks to Rick who posted that url on another thread...
Would be nice to see some PR from Ariad...has not been
one of my best investments...I have a little stock since
$2...and not too happy that I got into the warrants
obviously.
--Mike
|
